SEC Form 4 · accession 0001562180-19-001850
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimi Iguchi
Officer — CFO & Treasurer
Period of report
Mar 8, 2019
Accepted (ET)
Mar 11, 2019 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 8, 2019 | M | 4,723 | $0.45 | A | 6,136 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.45 | Mar 8, 2019 | M | 4,723 | D | — | Sep 24, 2023 | Common Stock | 4,723 | 0 | D |
Explanation of responses
- F1The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on September 16, 2017.